Wells Fargo & Company MN reduced its stake in shares of Voyager Therapeutics (NASDAQ:VYGR) by 13.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 390,983 shares of the company’s stock after selling 58,542 shares during the period. Wells Fargo & Company MN owned 1.21% of Voyager Therapeutics worth $7,347,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. MetLife Investment Advisors LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $128,000. Lazard Asset Management LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $334,000. D.A. Davidson & CO. purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $366,000. Virtus Fund Advisers LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $392,000. Finally, Ardsley Advisory Partners purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $415,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.
VYGR has been the topic of a number of analyst reports. BidaskClub cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 9th. BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Voyager Therapeutics in a research report on Sunday, March 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $40.00 price objective on shares of Voyager Therapeutics in a research report on Monday, March 12th. Wedbush downgraded Voyager Therapeutics from an “outperform” rating to a “neutral” rating and set a $29.00 target price on the stock. in a research note on Monday, March 12th. Finally, Canaccord Genuity set a $35.00 target price on Voyager Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 14th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $30.83.
NASDAQ:VYGR opened at $22.90 on Monday. Voyager Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.91. The company has a market capitalization of $727.22 million, a price-to-earnings ratio of -8.67 and a beta of 3.00.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.52). Voyager Therapeutics had a negative return on equity of 69.92% and a negative net margin of 768.99%. The firm had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.00 million. sell-side analysts expect that Voyager Therapeutics will post -2.71 earnings per share for the current year.
In other news, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $18.38, for a total value of $45,049.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 33.60% of the stock is currently owned by insiders.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics (NASDAQ:VYGR).
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.